Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer

• Published in: Scientific reports 2024-07, Vol.14 (1), p.17459-12, Article 17459
• Main Authors: Ibanez, Kristen R., Donohue, Duncan, Malys, Tyler, Lee, Jung-Min
• Format: Article
• Language: English
• Subjects: 631/67; 631/67/1517/1709; 692/308; 692/4017; 692/4028; 692/53; 692/53/2423; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Breast cancer; CA-125 Antigen - blood; Cell cycle; Checkpoint Kinase 1 - antagonists & inhibitors; CHK1 protein; Female; Gynecological cancer; Humanities and Social Sciences; Humans; Medical prognosis; Membrane Proteins; Middle Aged; multidisciplinary; Neoplasm Recurrence, Local - drug therapy; Ovarian cancer; Ovarian Neoplasms - blood; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyrazines - pharmacology; Pyrazines - therapeutic use; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; Response Evaluation Criteria in Solid Tumors; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-68338-2

We investigated the association of CA125 response with prognosis and RECIST response/progressive disease (PD) criteria in recurrent high grade serous ovarian cancer (HGSOC) patients treated with a cell cycle checkpoint kinase 1 inhibitor (CHK1i), prexasertib. 81 patients had measurable disease per RECISTv1.1, of which 72 and 70 were measurable by Gynecologic Cancer InterGroup (GCIG) CA125 response and PD criteria, respectively. Univariate and multivariate analyses showed that GCIG CA125 response (n = 32) is associated with improved progression-free survival (PFS) and overall survival (OS) compared to no GCIG CA125 response (n = 40) (median PFS 8.0 vs. 3.5 months [HR: 0.30, 95% CI: 0.18–0.51, p